Prevents osteoporosis in postmenopausal women (1.1, 1.2). ANDA 90124, held by Aurobindo Pharma. Alendronate Sodium.
As of Nov 16, 2026, ANDA 90124 (Alendronate Sodium), held by Aurobindo Pharma, was first approved by FDA on Aug 4, 2008, with 14 approved supplements and 0 published complete response letters.
Alendronate sodium is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women (1.1, 1.2) Treatment to increase bone mass in men with osteoporosis Treatment of glucocorticoid-induced osteoporosis Treatment of Paget's disease of bone Limitations of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 4, 2008 | Original application | Approved | None posted |
| Alendronate SodiumEQ 10MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Apr 15, 2026 | Supplement 23Labeling · Standard review | Approved | None posted |
| Sep 27, 2024 | Supplement 22Manufacturing | Approved | None posted |
| Jun 6, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Apr 8, 2016 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jul 22, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 22, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jul 22, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 5, 2013 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 25, 2012 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 17, 2012 | Supplement 5Labeling | Approved | None posted |
| Apr 6, 2011 | Supplement 4Labeling | Approved | None posted |
| Feb 15, 2011 | Supplement 3Labeling | Approved | None posted |
| Aug 24, 2010 | Supplement 2Labeling | Approved | None posted |
| Feb 19, 2009 | Supplement 1Labeling | Approved | None posted |
| Aug 4, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters